Kura Oncology (NASDAQ:KURA) Receives Buy Rating from TD Cowen

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating restated by TD Cowen in a research report issued to clients and investors on Thursday,Benzinga reports.

KURA has been the topic of several other reports. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Thursday. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. UBS Group began coverage on Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price on the stock. Finally, Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and reduced their price target for the company from $26.00 to $19.00 in a research report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.38.

Kura Oncology Trading Up 7.4 %

Kura Oncology stock opened at $10.80 on Thursday. The stock has a 50-day moving average price of $18.08 and a 200 day moving average price of $19.76. The company has a market capitalization of $839.85 million, a price-to-earnings ratio of -4.66 and a beta of 0.86. Kura Oncology has a 52 week low of $9.06 and a 52 week high of $24.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in KURA. Avoro Capital Advisors LLC lifted its holdings in Kura Oncology by 29.2% during the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares in the last quarter. Suvretta Capital Management LLC lifted its stake in Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after buying an additional 583,155 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Kura Oncology by 50.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after buying an additional 577,732 shares in the last quarter. Sofinnova Investments Inc. lifted its stake in Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after buying an additional 323,303 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after buying an additional 302,000 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.